Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of GW42003 and GW42004 formulations for dyslipidaemia in type 2 diabetes
2010-020458-33Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Jun 2010
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol and tetrahydrocannabivarin in lipid disorder and type 2 diabetes mellitus (T2DM) (5 arms), sponsored by GW Pharmaceuticals. Primary endpoint: Change from baseline in serum HDL cholesterol concentration at Day 91. Started Jun 2010; status: completed.
02
Drugs
cannabidioltetrahydrocannabivarin
03
Conditions
lipid disordertype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-020458-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020458-33.